USD 73.11
(4.55%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 1.48 Billion USD | -33.26% |
2022 | 2.23 Billion USD | -9.64% |
2021 | 2.46 Billion USD | 83.71% |
2020 | 1.34 Billion USD | -26.8% |
2019 | 1.83 Billion USD | 106.29% |
2018 | 890 Million USD | -24.7% |
2017 | 1.18 Billion USD | 12.81% |
2016 | 1.04 Billion USD | 3.17% |
2015 | 1.01 Billion USD | 2.93% |
2014 | 986.78 Million USD | 17.57% |
2013 | 839.3 Million USD | 4.21% |
2012 | 805.4 Million USD | -0.24% |
2011 | 807.36 Million USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | -100.0% |
2007 | 400 Million USD | 0.0% |
2006 | - USD | -100.0% |
2005 | 54 Thousand USD | 0.0% |
2004 | - USD | -100.0% |
2003 | 24.99 Million USD | -2.42% |
2002 | 25.62 Million USD | 4242.37% |
2001 | 590 Thousand USD | -33.46% |
2000 | 886.62 Thousand USD | 0.0% |
1999 | - USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 1.49 Billion USD | 0.07% |
2024 Q3 | 2.6 Billion USD | 33.42% |
2024 Q2 | 1.49 Billion USD | 0.0% |
2023 Q4 | 1.48 Billion USD | -31.92% |
2023 Q3 | 2.18 Billion USD | -1.22% |
2023 FY | 1.48 Billion USD | -33.26% |
2023 Q1 | 2.23 Billion USD | 0.13% |
2023 Q2 | 2.21 Billion USD | -0.9% |
2022 Q3 | 1.24 Billion USD | -2.13% |
2022 Q4 | 2.23 Billion USD | 79.49% |
2022 FY | 2.23 Billion USD | -9.64% |
2022 Q1 | 2.04 Billion USD | -17.21% |
2022 Q2 | 1.27 Billion USD | -37.87% |
2021 Q2 | 2.38 Billion USD | 2.01% |
2021 FY | 2.46 Billion USD | 83.71% |
2021 Q1 | 2.33 Billion USD | 73.81% |
2021 Q4 | 2.46 Billion USD | -0.08% |
2021 Q3 | 2.47 Billion USD | 3.69% |
2020 FY | 1.34 Billion USD | -26.8% |
2020 Q1 | 1.34 Billion USD | -26.58% |
2020 Q2 | 1.34 Billion USD | -0.59% |
2020 Q4 | 1.34 Billion USD | 0.0% |
2020 Q3 | 1.34 Billion USD | 0.3% |
2019 Q4 | 1.83 Billion USD | 0.77% |
2019 FY | 1.83 Billion USD | 106.29% |
2019 Q3 | 1.82 Billion USD | 0.22% |
2019 Q1 | 1.83 Billion USD | 105.62% |
2019 Q2 | 1.81 Billion USD | -0.66% |
2018 FY | 890 Million USD | -24.7% |
2018 Q1 | 710 Million USD | -39.93% |
2018 Q2 | 723 Million USD | 1.83% |
2018 Q3 | 860 Million USD | 18.95% |
2018 Q4 | 890 Million USD | 3.49% |
2017 Q1 | 1.05 Billion USD | 0.69% |
2017 Q4 | 1.18 Billion USD | 0.17% |
2017 Q3 | 1.18 Billion USD | 0.94% |
2017 Q2 | 1.16 Billion USD | 10.81% |
2017 FY | 1.18 Billion USD | 12.81% |
2016 FY | 1.04 Billion USD | 3.17% |
2016 Q4 | 1.04 Billion USD | 0.68% |
2016 Q3 | 1.04 Billion USD | 0.91% |
2016 Q2 | 1.03 Billion USD | 0.85% |
2016 Q1 | 1.02 Billion USD | 0.69% |
2015 Q1 | 993.77 Million USD | 0.71% |
2015 FY | 1.01 Billion USD | 2.93% |
2015 Q2 | 1 Billion USD | 0.71% |
2015 Q4 | 1.01 Billion USD | 0.77% |
2015 Q3 | 1 Billion USD | 0.71% |
2014 Q3 | 979.83 Million USD | 0.71% |
2014 FY | 986.78 Million USD | 17.57% |
2014 Q4 | 986.78 Million USD | 0.71% |
2014 Q2 | 972.94 Million USD | 0.0% |
2014 Q1 | - USD | -100.0% |
2013 FY | 839.3 Million USD | 4.21% |
2013 Q4 | 839.3 Million USD | 1.04% |
2013 Q1 | 822.78 Million USD | 2.16% |
2013 Q2 | 822.16 Million USD | -0.07% |
2013 Q3 | 830.69 Million USD | 1.04% |
2012 FY | 805.4 Million USD | -0.24% |
2012 Q1 | 780.94 Million USD | -3.27% |
2012 Q3 | 797.16 Million USD | 1.03% |
2012 Q4 | 805.4 Million USD | 1.03% |
2012 Q2 | 789 Million USD | 1.03% |
2011 Q3 | 765.07 Million USD | 1.03% |
2011 FY | 807.36 Million USD | 0.0% |
2011 Q4 | 807.36 Million USD | 5.53% |
2011 Q2 | 757.27 Million USD | 16.13% |
2011 Q1 | 652.08 Million USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2008 Q1 | - USD | -100.0% |
2008 Q3 | 460 Thousand USD | -96.91% |
2008 Q4 | - USD | -100.0% |
2008 FY | - USD | -100.0% |
2008 Q2 | 14.88 Million USD | 0.0% |
2007 Q3 | 400 Million USD | 0.0% |
2007 Q1 | 400 Million USD | 0.0% |
2007 FY | 400 Million USD | 0.0% |
2007 Q2 | 400 Million USD | -0.0% |
2007 Q4 | 400 Million USD | 0.0% |
2006 FY | - USD | -100.0% |
2006 Q2 | - USD | -100.0% |
2006 Q1 | 25 Thousand USD | -53.7% |
2006 Q3 | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 FY | 54 Thousand USD | 0.0% |
2005 Q4 | 54 Thousand USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2004 FY | - USD | -100.0% |
2004 Q3 | - USD | -100.0% |
2004 Q2 | 24.79 Million USD | -0.41% |
2004 Q4 | - USD | 0.0% |
2004 Q1 | 24.89 Million USD | -0.42% |
2003 Q3 | 25.09 Million USD | -0.36% |
2003 Q4 | 24.99 Million USD | -0.36% |
2003 FY | 24.99 Million USD | -2.42% |
2003 Q1 | 25.27 Million USD | -1.35% |
2003 Q2 | 25.18 Million USD | -0.37% |
2002 FY | 25.62 Million USD | 4242.37% |
2002 Q1 | 25.61 Million USD | 4242.2% |
2002 Q2 | 25.53 Million USD | -0.34% |
2002 Q3 | 25.45 Million USD | -0.32% |
2002 Q4 | 25.62 Million USD | 0.66% |
2001 Q1 | 816 Thousand USD | -7.96% |
2001 Q2 | 743.08 Thousand USD | -8.94% |
2001 Q4 | 590 Thousand USD | -11.65% |
2001 Q3 | 667.78 Thousand USD | -10.13% |
2001 FY | 590 Thousand USD | -33.46% |
2000 Q2 | 1.02 Million USD | 0.0% |
2000 Q4 | 886.62 Thousand USD | -7.16% |
2000 Q1 | - USD | 0.0% |
2000 Q3 | 955.01 Thousand USD | -6.49% |
2000 FY | 886.62 Thousand USD | 0.0% |
1999 FY | - USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
uniQure N.V. | 130.06 Million USD | -1044.812% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -2512.831% |
Amicus Therapeutics, Inc. | 387.85 Million USD | -283.903% |
Atara Biotherapeutics, Inc. | 45.69 Million USD | -3158.705% |
bluebird bio, Inc. | 224.41 Million USD | -563.491% |
Cara Therapeutics, Inc. | 37.07 Million USD | -3915.75% |
Imunon, Inc. | 1.13 Million USD | -130595.089% |
Editas Medicine, Inc. | 24.37 Million USD | -6009.47% |
IQVIA Holdings Inc. | 12.95 Billion USD | 88.506% |
Mettler-Toledo International Inc. | 1.97 Billion USD | 24.629% |
Myriad Genetics, Inc. | 130.9 Million USD | -1037.51% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | -476.461% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -4385.48% |
Verastem, Inc. | 40.08 Million USD | -3614.514% |
Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 81.489% |
Waters Corporation | 2.3 Billion USD | 35.416% |
Thermo Fisher Scientific Inc. | 31.3 Billion USD | 95.244% |
Biogen Inc. | 7.18 Billion USD | 79.285% |
Nektar Therapeutics | 112.62 Million USD | -1222.087% |
Perrigo Company plc | 3.63 Billion USD | 59.012% |
Dynavax Technologies Corporation | 252.41 Million USD | -489.895% |
Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -45876.216% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -148800.0% |
Heron Therapeutics, Inc. | 173.75 Million USD | -756.964% |
Unity Biotechnology, Inc. | 23.53 Million USD | -6225.672% |
BioMarin Pharmaceutical Inc. | 593.09 Million USD | -151.056% |
Sangamo Therapeutics, Inc. | 33.51 Million USD | -4342.787% |
Evolus, Inc. | 120.35 Million USD | -1137.132% |
Adicet Bio, Inc. | 17.7 Million USD | -8311.004% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -48338.517% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 44.911% |
Esperion Therapeutics, Inc. | 501.54 Million USD | -196.882% |
FibroGen, Inc. | 89.69 Million USD | -1560.033% |
Agilent Technologies, Inc. | 2.73 Billion USD | 45.558% |
OPKO Health, Inc. | 222.03 Million USD | -570.618% |
Homology Medicines, Inc. | 43.17 Million USD | -3348.675% |
Geron Corporation | 35.05 Million USD | -4148.096% |
Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 36.45% |
Exelixis, Inc. | 189.94 Million USD | -683.915% |
Viking Therapeutics, Inc. | 936 Thousand USD | -158981.197% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | 96.74 Million USD | -1439.066% |
Zoetis Inc. | 6.56 Billion USD | 77.316% |
Axsome Therapeutics, Inc. | 178.07 Million USD | -736.188% |
Abeona Therapeutics Inc. | 4.4 Million USD | -33725.534% |
Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -105.464% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | -4255.075% |
Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -6.329% |
Sarepta Therapeutics, Inc. | 1.13 Billion USD | -31.477% |
Corcept Therapeutics Incorporated | - USD | -Infinity% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 0.684% |
Blueprint Medicines Corporation | 610.96 Million USD | -143.714% |
Insmed Incorporated | 1.19 Billion USD | -24.775% |
TG Therapeutics, Inc. | 100.11 Million USD | -1387.245% |
Incyte Corporation | 29.16 Million USD | -5005.96% |
Emergent BioSolutions Inc. | 446.5 Million USD | -233.483% |